Leica Biosystems has entered into an agreement with Commissioning Agents (CAI) to offer CAI's Good Laboratory Practices Installation Qualification, Operational Qualification, Performance Qualification (GLP IQOQPQ) validation services, across the globe.
Under the deal, CAI will specifically carry out GLP IQOQPQ validation services for Leica Biosystems Aperio ePathology slide scanners and related software.
Leica Biosystems Aperio ePathology vice-president Anne Brumme said there is a growing demand for the company’s customers to validate their digital pathology products in a GLP environment, especially for the pre-clinical drug development market.
"CAI, experts in hardware and software validation, will enable Leica Biosystems to service its global customers better than ever in a GLP environment," Brumme said.
"This is particularly important as our Aperio ePathology Solutions are increasingly being installed in global pharmaceutical and contract research organizations (CRO), which are looking to streamline its study workflows."
CAI vice-president Tulsa Scott said: "Commissioning Agents is well positioned to provide validation support as we are executing these services currently for biopharma clients worldwide."
The agreement with Leica Biosystems will expand CAI’s business within the pre-clinical segment of the industry.
Leica Biosystems provides workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives.
The company also offers anatomic pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting.
Image: CAI provides high quality IQOQPQ validation services for Aperio ePathology slide scanners and associated software. Photo: courtesy of PRNewswire.